Preface

Yuichi Hirose¹

Published online: 28 April 2020

© The Japan Society of Brain Tumor Pathology 2020

The 37th Annual Meeting of the Japanese Society for Pathology of Brain Tumor was held in Nagoya from May 31 to June 1, 2019. The Society is led by neurosurgeons and pathologists who are involved in the treatment and research of brain tumors.

The main theme of the Meeting was “the microenvironment of brain tumors” that aimed to promote discussion about the cellular response between the host and the tumor including mechanism of gene regulation and immune reactions.

We invited three pioneers in tumor genetics/biology from USA. Dr. Kenneth Aldape (NIH/NCI), a leading expert in genetic analysis of brain tumors and a key member of the WHO brain tumor classification 2016, Dr. Joseph Costello (UCSF Brain Tumor Research Center) who has published many papers including DNA methylation analysis, and Dr. Hideho Okada (UCSF Brain Tumor Research Center), a leader in the field of tumor immunity. They gave us educational lectures on cutting-edge research. Dr. Aldape is probably the person who has the most genetic abnormalities in brain tumors in the back department, but IDH wild type grade II/III which is one of the problems in the 2016 version of the WHO brain tumor classification. He introduced his recent findings on astrocytomas, and gave a lecture to deepen his understanding of the prospects for molecular diagnosis of brain tumors in the future. Dr. Costello gave a lecture on the diversity of genetic abnormalities in brain tumors and the mechanism of tumor immortalization, and, I believe, gave us valuable knowledge for the future development of brain tumor pathology. In addition, Dr. Okada’s lecture was also very meaningful about the issues to be considered in modern brain tumor pathology because the recent clinical

introduction of immune checkpoint inhibitors in the field of cancer pharmacotherapy has attracted a great deal of interest in tumor immunity. Although immunotherapy of brain tumors is still developing, the interaction between tumors and immune cells in the brain is exactly one of the major themes of this study, which is to discuss the microenvironment of brain tumors.

In addition, I thank many attendees for their submission of their study and for the discussion through the Meeting. Without them, the society could not be successful.

I would like to express my sincere gratitude to Prof. Takashi Komori, the editor-in-chief of Brain Tumor Pathology for editing this special issue, and, finally, would like to thank Dr. Yuya Nishiyama and medical staff members of my Department, who worked hard to prepare and run the conference.

Yuichi Hirose (President), The 37th Annual Meeting of the Japan Society of Brain Tumor Pathology.

✉ Yuichi Hirose
yhirose@fujita-hu.ac.jp

¹ Department of Neurosurgery, Fujita Medical University, Toyoake, Japan

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.